BTEE:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (USD)

ETF | Others |

Last Closing

USD 5.9665

Change

0.00 (0.00)%

Market Cap

USD 0.49B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-28 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

-1.04 (-0.37%)

USD 292,109.69B
0R1O:LSE Amazon.com Inc.

+4.50 (+2.37%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

-1.28 (-0.91%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.08 (+0.42%)

USD 559.82B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.06 (+0.44%)

USD 500.71B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

+0.70 (+1.06%)

USD 266.08B
0QZO:LSE 0QZO

+0.15 (+0.16%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

+0.11 (+0.35%)

USD 204.07B
0QZ3:LSE Qualcomm Inc.

-4.06 (-2.34%)

USD 202.26B

ETFs Containing BTEE:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.53% 12% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.53% 12% F 24% F
Trailing 12 Months  
Capital Gain -1.47% 22% F 39% F
Dividend Return 0.23% 39% F 69% C-
Total Return -1.24% 21% F 38% F
Trailing 5 Years  
Capital Gain 23.97% 49% F 60% D-
Dividend Return 0.66% 25% F 16% F
Total Return 24.63% 47% F 58% F
Average Annual (5 Year Horizon)  
Capital Gain 6.60% 61% D- 65% D
Dividend Return 6.71% 60% D- 64% D
Total Return N/A 100% F 98% N/A
Risk Return Profile  
Volatility (Standard Deviation) 19.77% 36% F 50% F
Risk Adjusted Return 33.92% 56% F 68% D+
Market Capitalization 0.49B 70% C- 60% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.